Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations ...

Some patients with bronchiectasis also suffered with asthma (35%) or lung cancer (7%) at the same time, researchers noted. After analyzing the organisms in pulmonary samples from 56% of the total ...

Plumes of Saharan dust are expected to sweep over Florida in the coming days, which can cause real problems for people with ...

Neutrophils are the core airway inflammatory cell in bronchiectasis ... and 18.7% a history of asthma. Among the secondary endpoints, time to the first exacerbation was longer with brensocatib ...

Bronchiectasis impacts up to 500,000 Americans, but there is often misdiagnosis or delayed diagnosis as the condition can present similarly to other pulmonary conditions such as COPD or asthma.

Amlitelimab reduced asthma exacerbations by over 70% in biomarker ... Finally, itepekimab is being explored in a phase 2 study in bronchiectasis, with the readout anticipated in 2026.

phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026 Amlitelimab: clinically meaningful efficacy in asthmaPreliminary results from the TIDE-Asthma phase 2 study (clinical study ...

Patients were required to have a diagnosis of COPD, asthma, or bronchiectasis for at least 6 months and had to be current smokers. Patients were excluded if they had active psychiatric disorders ...

In asthma, amlitelimab shows potential as an ... in a phase 2 study (clinical study identifier: NCT06280391) in bronchiectasis, with the readout anticipated in 2026. Amlitelimab is a fully human ...